新型抗原靶点CAR-T细胞治疗前30天感染并发症特征
该回顾性研究分析了5项I期CAR-T临床试验中162例儿童和成人患者,涵盖CD19、CD22、GD2和BCMA靶点,发现32.7%的患者在淋巴细胞清除化疗至第30天发生感染,多数感染发生在回输后30天内,CD22和BCMA CAR-T感染比例较高,多因素分析仅既往治疗线数和近期感染与感染风险独立相关。
要点
- CAR-T治疗后30天内感染发生率32.7%,多数发生在回输后30天内。
- CD22和BCMA CAR-T感染比例较高,多发性骨髓瘤患者感染比例最高。
- 既往治疗线数和淋巴细胞清除前100天内感染是独立危险因素。
核心结论
- CAR-T治疗前30天感染常见但4级感染罕见,不同靶点和疾病感染风险存在差异。
研究设计与样本
- 回顾性分析5项I期CAR-T临床试验,共162例儿童和成人患者,靶点包括CD19、CD22、GD2和BCMA。
主要发现
- 53例(32.7%)发生76次感染,其中61次(80.3%)发生在回输后第0至30天。
- CD22 CAR-T感染比例43.4%(23/53),BCMA CAR-T为37.5%(9/24)。
- 多发性骨髓瘤患者感染比例37.5%(9/24),急性淋巴细胞白血病为35.3%(36/102)。
- 4级感染罕见,共4例(2.5%)。
- 回输后30天内最常见感染类型为菌血症和细菌性部位感染。
关键数值与推荐
- 单因素分析中,既往治疗线数增加、淋巴细胞清除前100天内感染、使用糖皮质激素或托珠单抗、发热伴中性粒细胞减少与感染风险升高相关。
- 多因素分析仅既往治疗线数和近期感染与感染风险升高独立相关。
临床怎么用
- 对既往多线治疗或近期感染患者应加强CAR-T后30天内感染监测与预防。
局限性
- 回顾性研究,样本来自5项I期临床试验,部分靶点样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections are a known complication of chimeric antigen receptor (CAR) T-cell therapy with data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to evolve, infection risks and management thereof will become increasingly important to optimize outcomes across the spectrum of antigens and disease targeted. We retrospectively characterized infectious complications occurring in 162 children and adults treated among 5 phase 1 CAR T-cell clinical trials. Trials included targeting of CD19, CD22, disialoganglioside (GD2) or B-cell maturation antigen (BCMA). Fifty-three patients (32.7%) had 76 infections between lymphocyte depleting (LD) chemotherapy and day 30 (D30); with the majority of infections (61, 80.3%) occurring between day 0 (D0) and D30. By trial, the highest proportion of infections was seen with CD22 CAR T cells (n = 23/53; 43.4%), followed by BCMA CAR T cells (n = 9/24; 37.5%). By disease, patients with multiple myeloma had the highest proportion of infections (9/24; 37.5%) followed by acute lymphoblastic leukemia (36/102; 35.3%). Grade 4 infections were rare (n = 4; 2.5%). Between D0 and D30, bacteremia and bacterial site infections were the most common infection type. In univariate analysis, increasing prior lines of therapy, recent infection within 100 days of LD chemotherapy, corticosteroid or tocilizumab use, and fever and neutropenia were associated with a higher risk of infection. In a multivariable analysis, only prior lines of therapy and recent infection were associated with higher risk of infection. In conclusion, we provide a broad overview of infection risk within the first 30 days post infusion across a host of multiple targets and diseases, elucidating both unique characteristics and commonalities highlighting aspects important to improving patient outcomes.
引用
- Mikkilineni L, Yates B, Steinberg SM, et al. Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Adv. 2021. PMID: 34619768. doi:10.1182/bloodadvances.2021004896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。